The investment round will fund the first clinical trials for an innovative therapeutic modality designed to overcome drug resistance in patients with solid tumors.
The US approval of Nemluvio marks a major milestone for Galderma, a Swiss company developing treatments for a wide range of conditions affecting the skin.
The FDA has given the green light to Lymphir, the first immunotherapy for the treatment of cutaneous T-cell lymphoma (CTCL) to get approval in over five years.
The agreement will give Genentech access to Sangamo’s capsid delivery platform and epigenetic regulation technology with applications in neurodegenerative disease.
With the FDA’s endorsement, Amgen and AstraZeneca are getting closer to adding chronic obstructive pulmonary disease (COPD) as a new indication to Tezspire.
In a significant move set to reshape the landscape of drug discovery, NovAliX, a leading Contract Research Organization (CRO) specializing in drug development, has entered a strategic partnership with Bruker, a global leader in scientific instruments.
Experience with severe mental health disorders in close friends and family gave Sam Clark the drive to found Terran Biosciences to explore new approaches to therapeutics in neuropsychiatry.
The FDA has granted accelerated approval to Adaptimmune’s Tecelra, a T cell therapy for the treatment of synovial sarcoma when other lines of treatment do not work.
Pfizer will let go of 150 employees at its Sanford, US site that were involved in the development of a gene therapy for Duchenne muscular dystrophy that recently failed in a phase 3 clinical trial.
The Bateman Horne Center of Excellence (BHC) has established itself as a trusted leader in the clinical care, provider education, patient advocacy, and research of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and long COVID.
BeiGene, a global oncology company, has announced the opening of its flagship US facility, which will expand the company’s biologics manufacturing capabilities and clinical research and development activities.
A committee from the European Medicines Agency (EMA) has voted against granting Leqembi (lecanemab) a marketing authorization due to the risk of serious side effects associated with the treatment.
As advanced therapies drive increasing market consolidation, the US giant Agilent Technologies has acquired the Canadian contract development and manufacturing organization (CDMO) BIOVECTRA for $925 million.
When she was young, Suzanne used to love hearing her father, a cardiologist, talking to his colleagues on the phone about patients and the care they needed.
Data integrity is a paramount concern for pharmaceutical manufacturers, particularly as they navigate the complexities of modern production with legacy equipment.
The fundraising will support the development of the company’s technology platform for silencing RNA (siRNA), which has the potential to enable dosing patients every six months to treat a wide range of conditions.
The contract development and manufacturing organization (CDMO) arm of the Israeli company Pluri will deploy automated and 3D cell expansion technology to produce cell therapies developed by compatriot firm Kadimastem.
Ionis Pharmaceuticals antisense therapy for Angelman syndrome achieved good early safety and efficacy results and the company now plans to advance the therapy to phase 3.
Dr. Antonella Favit-VanPelt, a distinguished neurologist, has had a lifelong passion for understanding the 'why' behind sickness, ignited by her childhood curiosity.
Contract development and manufacturing organizations (CDMOs) perform vital services for the biopharmaceutical industry – a role that is growing as cell and gene therapies gain momentum. Here are five of the top CDMOs bringing advanced therapies toward...
CordenPharma, a US-based contract development and manufacturing organization (CDMO), will be making a €900 million investment over the next three years into expanding its peptide technology platform at its US and Europe sites.
Dr. Catherine Duggan, chief executive officer of the International Pharmaceutical Federation (FIP), has been at the helm since June 2018, based in The Hague.
During her teenage years, Dr. Jasmina Jankicevic harbored a passion for researching and advocating improved methods to maintain health and well-being for both children and adults.
Thermo Fisher’s cutting-edge ultra-cold facility in Bleiswijk, Netherlands, aims to accelerate advanced therapies development by offering comprehensive cold and ultra-cold services.
RNA therapeutics have emerged as a transformative approach to treating many conditions, but the industry still typically relies on inefficient batch manufacturing methods.
Andelyn Biosciences, a leading cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has been chosen by UMass Chan Medical School to manufacture clinical-grade AAV9-CSA vector using its suspension AAV Curator Platform...
As the industry continues its fascination with antibody-drug conjugates (ADCs), UK startup Myricx Bio heralds European biotech’s biggest Series A round this year.
CureVac has signed a new licensing agreement with GSK shortly after announcing the decision to reduce its workforce by 30% and refocus its research and development priorities.
Her grandmother was in a marching band in the early 1900s and mom was only one of two in her graduating class as a pharmacist and her dad, an inventor with more than 30 patents.
Eli Lilly has finally achieved FDA approval for its monoclonal antibody Alzheimer’s therapy donanemab, bringing new competition to the field for Eisai and Biogen.
RNA therapeutics have emerged as a transformative approach to treating many conditions, but the industry still typically relies on inefficient batch manufacturing methods.
Hot on the heels of last year’s EU approval of Hemgenix, the first gene therapy for the blood disorder hemophilia B, the UK and Denmark are the latest European nations to take steps to pay for the treatment.
The US FDA has delayed approval of Rocket Pharmaceuticals’ gene therapy for treatment of a rare immune condition known as leukocyte adhesion deficiency, citing a need for more information about the manufacturing process.
